Pivotal data are due soon with the Claudin18.2-targeting ADC sonesitatug vedotin.
ApexOnco Front Page
Recent articles
JSKN027 will become the first ADC with this mechanism to enter human trials.
New pivotal trials will soon start for LaNova’s ADC and FutureGen’s MAb.
Lynparza/Imfinzi won’t progress in ovarian cancer, and another ceralasertib study fails.
The company’s latest phase 3 for its biparatopic ADC is in colorectal cancer.
Cogent joins OnKure with a clinical-stage H1047Rm-specific PI3Kα inhibitor.
A phase 3 trial is downgraded, and the second line now looks like the main focus for turmetabart adizutecan.
After a phase 3 push the livmoniplimab plan falters.
